AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
Clinical trial NCT06938503 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06938503
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-21
- Primary completion
- 2028-04-25
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.